China Pharma Holdings (CPHI) Capital Expenditures Growth (1y) (2011 - 2025)
China Pharma Holdings (CPHI) Capital Expenditures Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 8.33% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | -19.86% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -1.95% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 73.63% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -0.19% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | -37.60% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | -42.11% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | China Pharma Holdings | 41.38 Mn | 41.08 Mn | 83,566.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -97.68% |
| Sep 30, 2025 | 106.63% |
| Dec 31, 2024 | 331.74% |
| Sep 30, 2024 | -113.67% |
| Dec 31, 2023 | 116.60% |
| Sep 30, 2023 | -73.29% |
| Jun 30, 2023 | -102.57% |
| Mar 31, 2023 | -4,123.29% |
| Dec 31, 2022 | -486.45% |
| Sep 30, 2022 | -39.29% |
| Dec 31, 2021 | 103.03% |
| Sep 30, 2021 | 60.34% |
| Dec 31, 2020 | -562.70% |
| Sep 30, 2020 | 2,026.29% |
| Jun 30, 2020 | 150,299.39% |
| Mar 31, 2020 | 370.85% |
| Dec 31, 2019 | 182.18% |
| Sep 30, 2019 | 264.21% |
| Jun 30, 2019 | -101.24% |
| Mar 31, 2019 | 1,936.56% |